FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the Month of June, 2024

 

Commission File Number 0-51504

 

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F Form 40-F

 

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement on Form F-3 (File Nos. 333-276168), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

   
 

 

Exhibit Index

 

Exhibit No.   Description
     
Exhibit 99.1   Resignation of Chief Financial Officer and Company Secretary

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 28, 2024

 

GENETIC TECHNOLOGIES LIMITED  
   
By: /s/ Kathryn Andrews  
Name: Kathryn Andrews  
Title: Company Secretary  

 

   

 

 

Exhibit 99.1

 

ASX Market Announcement

 

Resignation of Chief Financial Officer and Company Secretary

 

Melbourne, Australia, June 28, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, advises that Kathryn Andrews has provided her notice of resignation as Chief Financial Officer (CFO) and Company Secretary of the Company.

 

The Company will commence a search for a new CFO and Company Secretary.

 

Simon Morriss, CEO of GTG commented on behalf of the GTG team, “We thank Kathryn for her contributions in her time at GTG and we wish her the very best in her next endeavours”.

 

- END -

 

Authorised for release by the Board of Directors.

 

Enquiries

 

Simon Morriss

Chief Executive Officer

E: investors@genetype.com

 

About Genetic Technologies Limited

 

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com